Moderna vaccine against the new coronavirus, which claimed the lives of more than 741 million people worldwide, was the fourth among other vaccines on the purchase of a large party which was a deal with the U.S. government. Vaccine Moderna is the final stage of testing on humans.
Stock Moderna (MRNA), an increase of 252,6% YTD, up 9% before the opening of trading on Wednesday (at the time of writing) on the background of the announcement by President Donald trump signature with big government deal for the supply of 100 million doses of its vaccine mRNA-1273 vs COVID-19.
According to a press release of the company Moderna on Tuesday, the deal amounts to $1.53 billion, conditions also allows the Federal government to buy up to 400 million additional doses.
At the same time, the U.S. government has already invested $955 million in the development of a vaccine Moderna, resulting in a total volume of attracted investments reached $2,48 billion.
Currently, the vaccine Moderna from a deadly disease is at the final phase of the study, tests of its efficacy and safety is conducted on 30 000 volunteers. If you follow the schedule, according to Moderna, a company may declare final results the final study in October.
Previously, the company announced plans to deliver about 500 million doses of vaccine this year, and possibly up to 1 billion doses a year starting in 2021.
“We appreciate the trust of the US government to our platform mRNA vaccine and continued support,” – said in a press release, the General Director of Moderna Stefan Bansal.
Commenting on the recent quarterly report, Moderna Bansal said that the company will set the price of the vaccine “significantly below cost” in the period of the pandemic and will assess it at market value as soon as the virus is brought under control.
Deal of the US government with Moderna follows similar agreements with pharmaceutical giants Pfizer (PFE), Johnson and Johnson (JNJ) and other drugmakers against their potential vaccines against COVID-19.
“We invest in the development and production of six of the best vaccine candidates to ensure fast delivery. The military is ready to work, they are ready to deliver the vaccine to the Americans once it is fully approved by the FDA (Department of food and drug administration), and we are very close to this approval,” said trump at a press conference in the White house.
Earlier, the Ministry of health and social services of the United States to supply 100 million doses of vaccine against COVID-19 the sum of $1.95 billion received by Pfizer in partnership with BioNTech (BNTX), the deal also includes an option to purchase 500 million additional doses.
The government’s deal with Johnson & Johnson is also designed to supply 100 million doses with the possibility of ordering another 200 million, but will cost US cheaper – about $1 billion.
Another government deal was concluded with Sanofi and GlaxoSmithKline worth up to $2.1 billion for the development and supply of 100 million doses of the potential vaccine against the coronavirus with an option to purchase an additional 500 million doses.
Vaccines of all these companies, after the completion of the final research will be subject to approval process by the FDA (Department of food and drug administration).
Some candidates-vaccines, such as vaccine Pfizer and BioNTech received from the FDA the status of “fast track” that can help faster to get approval for production and sale.
White house adviser on issues of the pandemic, Dr. Anthony Fauci, publicly promised that the Americans will be granted effective and safe vaccine against COVID-19 before the end of this year.
